4.6 Review

A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm

Journal

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 107, Issue -, Pages 156-162

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2016.09.003

Keywords

Blastic plasmacytoid dendritic cell neoplasm; HyperCVAD; Allogeneic hematopoeitic cell transplant; Autologous hematopoeitic cell transplant

Ask authors/readers for more resources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells. It is a rare disease presenting across all ages with either skin or both skin and bone marrow involvement often conferring a poor prognosis. Though localized radiation has been used before, acute leukemia based regimens, remains the treatment of choice for induction of remission. Hematopoietic stem cell transplant, either autologous or allogeneic, is further required for attaining sustained remissions. Recently, a number of targeted therapies and newer drugs have been used as the molecular and genetic understanding of the disease have improved. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available